Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
暂无分享,去创建一个
Martin Posch | Franz König | Heiko Götte | Robin Ristl | Nicolás M Ballarini | Armin Schüler | M. Posch | R. Ristl | N. Ballarini | F. König | Heiko Götte | Armin Schüler
[1] A. Rong,et al. Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate , 2018, Pharmaceutical statistics.
[2] D. Schoenfeld. The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .
[3] P C Lambert,et al. Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method , 2017, Statistical methods in medical research.
[4] Tai-Tsang Chen. Statistical issues and challenges in immuno-oncology , 2013, Journal of Immunotherapy for Cancer.
[5] Huilin Chen,et al. Statistical Inference Methods for Two Crossing Survival Curves: A Comparison of Methods , 2015, PloS one.
[6] U Siebert,et al. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times? , 2018, Statistical methods in medical research.
[7] B. Logan,et al. Group sequential tests for long-term survival comparisons , 2015, Lifetime data analysis.
[8] T. Karrison. Versatile Tests for Comparing Survival Curves Based on Weighted Log-rank Statistics , 2016 .
[9] John D. Kalbfleisch,et al. Estimation of the average hazard ratio , 1981 .
[10] Werner Brannath,et al. Sequential tests for non-proportional hazards data , 2017, Lifetime data analysis.
[11] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[12] Tai-Tsang Chen,et al. Predicting analysis times in randomized clinical trials with cancer immunotherapy , 2016, BMC Medical Research Methodology.
[13] B. Jones,et al. Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects , 2018, Pharmaceutical statistics.
[14] Seung-Hwan Lee,et al. On the versatility of the combination of the weighted log-rank statistics , 2007, Comput. Stat. Data Anal..
[15] J. De Neve,et al. On the interpretation of the hazard ratio in Cox regression , 2019, Biometrical journal. Biometrische Zeitschrift.
[16] R. Tarone,et al. On the distribution of the maximum of the longrank statistic and the modified Wilcoxon statistic , 1981 .
[17] M. Schemper,et al. The estimation of average hazard ratios by weighted Cox regression , 2009, Statistics in medicine.
[18] Takahiro Hasegawa,et al. Sample size determination for the weighted log‐rank test with the Fleming–Harrington class of weights in cancer vaccine studies , 2014, Pharmaceutical statistics.
[19] Song Yang,et al. Combining asymptotically normal tests : case studies in comparison of two groups , 2005 .
[20] B. Blumenstein,et al. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). , 2007, Vaccine.
[21] W. Brannath,et al. The Average Hazard Ratio – A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated? , 2018, Methods of Information in Medicine.
[22] Xun Chen,et al. Design and monitoring of survival trials in complex scenarios , 2018, Statistics in medicine.
[23] Daniel J. Wilson,et al. The harmonic mean p-value for combining dependent tests , 2019, Proceedings of the National Academy of Sciences.
[24] Takahiro Hasegawa,et al. Group sequential monitoring based on the weighted log‐rank test statistic with the Fleming–Harrington class of weights in cancer vaccine studies , 2016, Pharmaceutical statistics.
[25] V. Anagnostou,et al. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity , 2017, Clinical Cancer Research.
[26] R. Peto,et al. Rank tests of maximal power against Lehmann-type alternatives , 1972 .
[27] B. Freidlin,et al. Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Patrick Royston,et al. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.
[29] Ganesh B. Malla,et al. A new piecewise exponential estimator of a survival function , 2010 .